The Role of Alternative RNA Splicing on Endothelial Cell Barrier Dysfunction in Acute Respiratory Distress Syndrome
The Role of Alternative RNA Splicing on Endothelial Cell Barrier Dysfunction in Acute Respiratory Distress Syndrome
批准号:
10200082
负责人:
Sean Farrell Monaghan
金额:
$30.55万
依托单位国家:
美国
项目类别:
财政年份:
2013
资助国家:
美国
项目状态:
已结题
起止时间:
2013-09-20 至 2021-11-30
关键词:
AcidosisAcidsAcute Respiratory Distress SyndromeAlternative SplicingAnimal ModelBinding ProteinsBiological MarkersBiologyBloodBlood VesselsBurn injuryCancerousCardiopulmonaryCell LineCellsCenters of Research ExcellenceClinical TrialsComplicationCritical IllnessDataDevelopmentDiagnosticDiseaseEdemaEndothelial CellsEntropyEventExonsFunctional disorderGene ExpressionGenesGenetic TranscriptionGenotype-Tissue Expression ProjectHumanHypercapniaHypoxiaImmuneIn VitroIntensive Care UnitsIntronsJoining ExonsKnowledgeLabelLaboratoriesLungMalignant NeoplasmsMembraneMetabolic acidosisMicrovascular PermeabilityMolecularMorbidity - disease rateMusOutcomeOxygenPancreatitisPathogenesisPathway interactionsPatientsPermeabilityPhysiologicalPre-Clinical ModelProcessProtein IsoformsProtein SplicingProteinsRNARNA SplicingRegulationResolutionRespiratory AcidosisRoleSamplingSepsisShockSiteSmall Nuclear RibonucleoproteinsSpliceosomesStressStructure of parenchyma of lungSupportive careSyndromeTestingTherapeuticTidal VolumeTimeTranslationsTraumaVariantVascular PermeabilitiesWorkcecal ligation punctureeffective interventionimprovedimproved outcomemonolayermortalitymouse modelneoplastic cellpre-clinicalprotein expressionsurvival predictiontumorventilation
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Acute respiratory distress syndrome (ARDS) is a fatal critical illness with mortality rates greater than twenty
percent despite numerous clinical trials. It is therefore essential to develop better understanding of the basic
mechanisms of development of ARDS. ARDS is also unique in that it is a common pathway that occurs after
many disease processes that result in critical illness (shock from trauma or sepsis, burns, pancreatitis). ARDS
is characterized by vascular permeability leading to edema and accumulation of immune cells in the lung. The
increased vascular permeability is due to endothelial cell dysfunction and is the focus of this project. Much
work has focused on gene and protein expression with little known about changes in RNA splicing. RNA
splicing is a basic molecular function that occurs in all cells directly after RNA transcription, but before protein
translation in which introns are removed and exons are joined together. Over 90% of human genes with
multiple exons have alternative splicing events. With such a high rate of variation from the transcribed gene to
the produced protein, splicing must be under exquisite control, particularly in times of critical illness. Numerous
proteins are involved in the control of RNA splicing, including U1-70K. Preliminary data suggest that in the lung
there is no difference in gene expression, but rather multiple sites of alternative splicing of U1-70K. This is
similar to previous work showing that ARDS leads to alternative splicing of membrane bound proteins resulting
in a soluble form. We hypothesize that in ARDS alternative splicing alters the protein isoforms of U1-70K in
endothelial cells. This change in the isoforms, in turn, results in the microvascular permeability and
sequestration of edema and immune cells in the lungs during ARDS. Aim 1 will determine the isoforms of U1-
70K in endothelial cells and whether these isoforms are correlated with lung vascular permeability using a
mouse model of ARDS caused by cecal ligation and puncture. Aim 2 will determine the effects of the
physiological conditions (high acid, low oxygen) seen in ARDS on the U1-70K isoforms and endothelial cell
barrier dysfunction. Aim 3 will assess if U1-70K alternative splicing events present in the pre-clinical model are
present in samples from humans with critical illness. Better understanding of alternative RNA splicing in ARDS
will allow manipulation of this mechanism to improve outcomes and improve prediction of resolution of this
devastating syndrome.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Improving Sepsis Care with Deep RNA Sequencing Data
-
批准号:10665687
-
项目类别:
-
资助金额:$39.86万
-
财政年份:2021
-
负责人:Sean Farrell Monaghan
-
依托单位:
Improving Sepsis Care with Deep RNA Sequencing Data
-
批准号:10477386
-
项目类别:
-
资助金额:$39.9万
-
财政年份:2021
-
负责人:Sean Farrell Monaghan
-
依托单位:
Improving Sepsis Care with Deep RNA Sequencing Data
-
批准号:10274355
-
项目类别:
-
资助金额:$38.91万
-
财政年份:2021
-
负责人:Sean Farrell Monaghan
-
依托单位:
The Role of Alternative RNA Splicing on Endothelial Cell Barrier Dysfunction in Acute Respiratory Distress Syndrome
-
批准号:9979909
-
项目类别:
-
资助金额:$27.59万
-
财政年份:--
-
负责人:Sean Farrell Monaghan
-
依托单位:
国内基金
海外基金
登录
查看更多内容
具有抗癌活性的天然产物金霉酸(Aureolic acids)全合成与选择性构建2-脱氧糖苷键
-
批准号:22007039
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:王黎明
-
依托单位:
海洋放线菌来源聚酮类化合物Pteridic acids生物合成机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2019
-
负责人:朱义广
-
依托单位:
手性Lewis Acids催化的分子内串联1,5-氢迁移/环合反应及其在构建结构多样性手性含氮杂环化合物中的应用
-
批准号:21372217
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2013
-
负责人:袁伟成
-
依托单位:
对空气稳定的新型的有机金属Lewis Acids催化剂制备、表征与应用研究
-
批准号:21172061
-
项目类别:面上项目
-
资助金额:30.0万元
-
批准年份:2011
-
负责人:许新华
-
依托单位:
钛及含钛Lewis acids促臭氧/过氧化氢体系氧化性能的广普性、高效性及其机制
-
批准号:21176225
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2011
-
负责人:童少平
-
依托单位:
基于Zip Nucleic Acids引物对高度降解和低拷贝DNA检材的STR分型研究
-
批准号:81072511
-
项目类别:面上项目
-
资助金额:31.0万元
-
批准年份:2010
-
负责人:严江伟
-
依托单位:
海洋天然产物Makaluvic acids 的全合成及其对南海鱼虱存活的影响
-
批准号:30660215
-
项目类别:地区科学基金项目
-
资助金额:21.0万元
-
批准年份:2006
-
负责人:王世范
-
依托单位: